Aurobindo Pharma gets USFDA nod to manufacture Clopidogrel Tablets

18 May 2012 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Clopidogrel Tablets USP 75mg, which is being launched.

Clopidogrel Tablets USP 75mg is the generic equivalent of Aventis US LLC (Sanfoi’s) Plavix tablets USP 75mg. The product falls under the cardio-vascular (CVS) therapeutic category and is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease. The annual sale of the product is about $6.4 billion.

The company now has a total of 151 ANDA approvals (123 Final approvals including 1 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×